Kamada (KMDA) Non-cash Items (2012 - 2026)
Kamada's (KMDA) quarterly Non-cash Items came in at $5.0 million in Q2 2026, up 38.93% on a YoY basis from $3.6 million in Q2 2025, and down 33.45% quarter-over-quarter from $7.5 million in Q1 2026.
Analysis
Kamada (KMDA) Non-cash Items (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Non-cash Items for 8 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-cash Items rose 38.93% year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2026 stood at $23.2 million (up 6.97% YoY), and the FY2025 full-year result was $22.0 million, up 8.06% from the prior year.
- Non-cash Items retreated to $5.0 million in Q2 2026 per KMDA's latest filing, from $7.5 million in the prior quarter.
- Across five years, Non-cash Items topped out at $7.6 million in Q1 2025 and bottomed at $1.3 million in Q4 2023.
- Historically, Non-cash Items has averaged $5.0 million across 5 years, with a median of $5.0 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Non-cash Items tumbled 69.34% in 2023, then jumped 324.13% in 2024.
- Over 5 years, Non-cash Items stood at $4.3 million in 2022, then sank by 69.34% to $1.3 million in 2023, then surged by 324.13% to $5.6 million in 2024, then fell by 22.36% to $4.3 million in 2025, then grew by 15.05% to $5.0 million in 2026.
- According to Business Quant data, Non-cash Items over the past three periods registered $5.0 million, $7.5 million, and $4.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.99 Mn |
| Mar 31, 2026 | 7.50 Mn |
| Dec 31, 2025 | 4.34 Mn |
| Sep 30, 2025 | 6.41 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 7.63 Mn |
| Dec 31, 2024 | 5.59 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.67 Mn |
| Mar 31, 2024 | 5.15 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 4.53 Mn |
| Jun 30, 2023 | 4.21 Mn |
| Mar 31, 2023 | 5.61 Mn |
| Dec 31, 2022 | 4.30 Mn |
| Sep 30, 2022 | 5.49 Mn |
| Jun 30, 2022 | 4.98 Mn |
| Mar 31, 2022 | 5.28 Mn |
| Dec 31, 2021 | 3.71 Mn |
| Sep 30, 2021 | 1.45 Mn |